The_DT
use_NN
of_IN
interferon-gamma-treated_JJ
U937_NN
cells_NNS
in_IN
chemiluminescence_NN
assays_NNS
to_TO
detect_VB
red_JJ
cell_NN
,_,
platelet_NN
and_CC
granulocyte_NN
antibodies_NNS
of_IN
potential_JJ
clinical_JJ
significance_NN
._.

The_DT
chemiluminescent_JJ
-LRB-_-LRB-
CL_NN
-RRB-_-RRB-
response_NN
of_IN
interferon-gamma-treated_JJ
U937_NN
-LRB-_-LRB-
IFN-U937_NN
-RRB-_-RRB-
cells_NNS
to_TO
sensitized_VBN
target_NN
cells_NNS
has_VBZ
been_VBN
used_VBN
to_TO
detect_VB
red_JJ
cell_NN
,_,
platelet_NN
and_CC
granulocyte_NN
antibodies_NNS
._.

A_DT
clone_NN
of_IN
U937_NN
cells_NNS
was_VBD
selected_VBN
which_WDT
expressed_VBD
Fc_NN
receptor_NN
I_NN
-LRB-_-LRB-
Fc_NN
gamma_NN
RI_NN
-RRB-_-RRB-
and_CC
which_WDT
,_,
after_IN
incubation_NN
with_IN
IFN-gamma_NN
for_IN
72_CD
h_NN
,_,
was_VBD
capable_JJ
of_IN
generating_VBG
high_JJ
levels_NNS
of_IN
lucigenin-enhanced_JJ
CL_NN
._.

The_DT
CL_NN
responses_NNS
of_IN
IFN-U937_NN
cells_NNS
and_CC
peripheral_JJ
blood_NN
human_JJ
monocytes_NNS
to_TO
sensitized_VBN
red_JJ
cells_NNS
,_,
platelets_NNS
or_CC
granulocytes_NNS
were_VBD
then_RB
compared_VBN
._.

Assays_NNS
using_VBG
monocytes_NNS
or_CC
IFN-U937_NN
cells_NNS
were_VBD
of_IN
comparable_JJ
sensitivity_NN
for_IN
detection_NN
of_IN
antibodies_NNS
against_IN
all_DT
three_CD
types_NNS
of_IN
target_NN
cell_NN
._.

In_IN
addition_NN
,_,
the_DT
use_NN
of_IN
IFN-U937_NN
cells_NNS
reduced_VBD
interassay_JJ
variation_NN
and_CC
simplified_VBD
assay_NN
performance_NN
._.

The_DT
potential_JJ
clinical_JJ
usefulness_NN
of_IN
these_DT
CL_NN
assays_NNS
was_VBD
suggested_VBN
by_IN
the_DT
ability_NN
of_IN
both_CC
monocytes_NNS
and_CC
IFN-U937_NN
cells_NNS
to_TO
respond_VB
to_TO
red_JJ
cells_NNS
,_,
platelets_NNS
or_CC
granulocytes_NNS
sensitized_VBN
with_IN
sera_NN
from_IN
pregnant_JJ
women_NNS
whose_WP$
babies_NNS
had_VBD
either_CC
hemolytic_JJ
disease_NN
of_IN
the_DT
newborn_JJ
-LRB-_-LRB-
HDN_NN
-RRB-_-RRB-
,_,
alloimmune_JJ
thrombocytopenia_NN
or_CC
alloimmune_JJ
neutropenia_NN
respectively_RB
._.

In_IN
addition_NN
,_,
monocytes_NNS
and_CC
IFN-U937_NN
cells_NNS
both_DT
responded_VBD
to_TO
red_JJ
cells_NNS
sensitized_VBN
with_IN
antibodies_NNS
against_IN
a_DT
variety_NN
of_IN
specificities_NNS
of_IN
assumed_VBN
-LRB-_-LRB-
although_IN
not_RB
documented_VBN
-RRB-_-RRB-
clinical_JJ
significance_NN
for_IN
blood_NN
transfusion_NN
recipients_NNS
._.

In_IN
contrast_NN
,_,
monocytes_NNS
and_CC
IFN-U937_NN
cells_NNS
responded_VBD
only_RB
weakly_RB
to_TO
red_JJ
cells_NNS
sensitized_VBN
with_IN
either_DT
anti-D_JJ
in_IN
sera_NN
from_IN
mothers_NNS
of_IN
babies_NNS
unaffected_VBN
by_IN
HDN_NN
,_,
or_CC
with_IN
antisera_NNS
containing_VBG
high_JJ
titer_NN
antibodies_NNS
with_IN
specificities_NNS
not_RB
normally_RB
associated_VBN
with_IN
significantly_RB
reduced_VBN
red_JJ
cell_NN
survival_NN
._.

